Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages 85-

  De Giorgi, Valeria ^a,b   Monaco, Alessandro ^c   Worchech, Andrea ^c,d,e   Tornesello, MariaLina ^a   Izzo, Francesco ^a   Buonaguro, Luigi ^a   Marincola, Francesco M ^c   Wang, Ena ^c   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d GENELUX CORPORATION   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITALY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 70449715414     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-85     Document Type: Article

References (40)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
2. Davila JA, Petersena NJ, Nelson HA, El-Serag HB. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol 2003, 56:487-493. 10.1016/S0895-4356(02)00605-4, 12812824.
3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83. 10.1002/hep.1840360710, 12407579.
4. Romeo R, Colombo M. The natural history of hepatocellular carcinoma. Toxicology 2002, 181-182:39-42. 10.1016/S0300-483X(02)00252-4, 12505282.
5. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107. 10.1038/sj.onc.1206557, 12910247.
6. Buendia MA. Hepatitis B viruses and cancerogenesis. Biomed Pharmacother 1998, 52:34-43. 10.1016/S0753-3322(97)86239-7, 9755793.
7. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338. 10.1053/jlts.2003.50073, 12682882.
8. Colombo M. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res 1998, 154:337-344.
9. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-3043. 10.1002/cncr.11427, 12784339.
10. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004, 24:3-20.
11. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533-539. 10.1136/gut.2004.052167, 1774454, 15753540.
12. Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008, 44:847-853. 10.1016/j.ejca.2008.01.025, 18313290.
13. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999, 353:1253-1257. 10.1016/S0140-6736(98)09148-X, 10217098.
14. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847. 10.1038/sj.onc.1209562, 16799625.
15. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998, 28:90-97. 10.1002/hep.510280114, 9657101.
16. Blum HE, Moradpour D. Viral pathogenesis of hepatocellular carcinoma. J Gastroenterol Hepatol 2002, 17(Suppl 3):S413-S420. 10.1046/j.1440-1746.17.s3.37.x, 12472973.
17. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002, 62:3939-3944.
18. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001, 61:2129-2137.
19. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001, 33:832-840. 10.1053/jhep.2001.23003, 11283847.
20. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18:457-459. 10.1038/74546, 10748532.
21. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
22. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235. 10.1038/73432, 10700174.
23. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999, 59:5464-5470.
24. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003, 163:505-516. 1868230, 12875971.
25. Safe S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 2001, 120:1-7. 10.1016/S0378-4274(01)00301-0, 11323156.
26. Okey AB. An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI. Toxicol Sci 2007, 98:5-38. 10.1093/toxsci/kfm096, 17569696.
27. Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 2009, 77:713-722. 10.1016/j.bcp.2008.08.031, 18817753.
28. Bock KW, Kohle C. Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol 2005, 69:1403-1408. 10.1016/j.bcp.2005.02.004, 15857604.
29. Tsunedomi R, Iizuka N, Hamamoto Y, Uchimura S, Miyamoto T, Tamesa T. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 2005, 27:661-667.
30. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001, 34:121-125. 10.1053/jhep.2001.25385, 11431742.
31. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003, 52:126-129. 10.1136/gut.52.1.126, 1773517, 12477773.
32. Jentsch S, Pyrowolakis G. Ubiquitin and its kin: how close are the family ties?. Trends Cell Biol 2000, 10:335-342. 10.1016/S0962-8924(00)01785-2, 10884686.
33. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 2002, 3:112-121. 10.1038/nrm731, 11836513.
34. Liu YC, Pan J, Zhang C, Fan W, Collinge M, Bender JR. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc Natl Acad Sci USA 1999, 96:4313-4318. 10.1073/pnas.96.8.4313, 16329, 10200259.
35. Shah JV, Cleveland DW. Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 2000, 103:997-1000. 10.1016/S0092-8674(00)00202-6, 11163175.
36. Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000, 21:2293-2297. 10.1093/carcin/21.12.2293, 11133821.
37. Gemma A, Hosoya Y, Seike M, Uematsu K, Kurimoto F, Hibino S. Genomic structure of the human MAD2 gene and mutation analysis in human lung and breast cancers. Lung Cancer 2001, 32:289-295. 10.1016/S0169-5002(00)00223-3, 11390010.
38. Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong TS. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003, 22:2592-2603. 10.1038/sj.onc.1206337, 12730673.
39. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009, 15:85-94. 10.2119/molmed.2008.00110, 2605622,2605622, 19098997.
40. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003, 10(Suppl 1):S59-S67. 10.1038/sj.cdd.4401163, 12655347.